231 related articles for article (PubMed ID: 14672079)
1. USA-Morocco deal may extend drug patents to 30 years.
Ahmad K
Lancet; 2003 Dec; 362(9399):1904. PubMed ID: 14672079
[No Abstract] [Full Text] [Related]
2. Patent necessity: intellectual property dilemmas in the biotech domain and treatment equity for developing countries.
Spectar JM
Houst J Int Law; 2002; 24(2):227-78. PubMed ID: 16189914
[No Abstract] [Full Text] [Related]
3. USA pressured to ease trade demands.
Ahmad K
Lancet; 2004 Mar; 363(9411):790. PubMed ID: 15022641
[No Abstract] [Full Text] [Related]
4. International intellectual property strategies for therapeutic antibodies.
Storz U
MAbs; 2011; 3(6):596-606. PubMed ID: 22123063
[TBL] [Abstract][Full Text] [Related]
5. Impact of the World Trade Organization TRIPS agreement on the pharmaceutical industry in Thailand.
Supakankunti S; Janjaroen WS; Tangphao O; Ratanawijitrasin S; Kraipornsak P; Pradithavanij P
Bull World Health Organ; 2001; 79(5):461-70. PubMed ID: 11417042
[TBL] [Abstract][Full Text] [Related]
6. TRIPS: whose interests are being served?
Kamal M; Bailey M
Lancet; 2003 Jul; 362(9380):260. PubMed ID: 12892952
[No Abstract] [Full Text] [Related]
7. Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad.
Luo J; Kesselheim AS
AMA J Ethics; 2016 Jul; 18(7):727-35. PubMed ID: 27437823
[TBL] [Abstract][Full Text] [Related]
8. Essential AIDS medications in India.
Thomas J
Issues Med Ethics; 2000; 8(2):62. PubMed ID: 16323350
[No Abstract] [Full Text] [Related]
9. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
10. Rx: higher prices.
Kosterlitz J
Natl J (Wash); 1993 Feb; 25(7):396-9. PubMed ID: 10125572
[TBL] [Abstract][Full Text] [Related]
11. Intellectual property and access to ART: unwise choice of terminology.
Stallman R
PLoS Med; 2006 Nov; 3(11):e509; author reply e510. PubMed ID: 17132062
[No Abstract] [Full Text] [Related]
12. TRIPS AGREEMENT ARTICLE 31(B): THE NEED FOR REVISION.
Effingham AM
Seton Hall Law Rev; 2016; 46(3):883-909. PubMed ID: 27066613
[No Abstract] [Full Text] [Related]
13. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
Correa CM
Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
[No Abstract] [Full Text] [Related]
14. Practical strategies to combat biopiracy.
Lawrence S; Skordis J
Lancet; 2004 Jan; 363(9403):166. PubMed ID: 14726178
[No Abstract] [Full Text] [Related]
15. International panel considers global patent system needs reassessment.
Ashraf H
Lancet; 2002 Sep; 360(9336):858. PubMed ID: 12243929
[No Abstract] [Full Text] [Related]
16. How do intellectual property law and international trade agreements affect access to antiretroviral therapy?
Westerhaus M; Castro A
PLoS Med; 2006 Aug; 3(8):e332. PubMed ID: 16881728
[TBL] [Abstract][Full Text] [Related]
17. Intellectual property. Challenges to India's pharmaceutical patent laws.
Sampat BN; Shadlen KC; Amin TM
Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
[No Abstract] [Full Text] [Related]
18. Patents & public health: international trade obligations and domestic policy development.
Amani B
Health Law Can; 2002 Feb; 22(3):76-84. PubMed ID: 11915591
[No Abstract] [Full Text] [Related]
19. The role of civil society in protecting public health over commercial interests: lessons from Thailand.
Ford N; Wilson D; Bunjumnong O; von Schoen Angerer T
Lancet; 2004 Feb; 363(9408):560-3. PubMed ID: 14975620
[No Abstract] [Full Text] [Related]
20. Health and intellectual property rights.
Correa CM
Bull World Health Organ; 2001; 79(5):381. PubMed ID: 11417031
[No Abstract] [Full Text] [Related]
[Next] [New Search]
